Developing new treatments for antibiotic-resistant infections and emerging diseases
Official title: Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases
Funded at Global Alliance for Tb Drug Development · NIH-11178808 · Data updated 2026-11-12
This study is working on developing new treatments for infections that are hard to treat because they don't respond to regular antibiotics, so patients can have better options for their health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Global Alliance for Tb Drug Development NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 10, 2024 |
| Project end | November 9, 2025 |
| Funding year | 2024 |
| Award (this year) | $2,475,623 |
| NIH project number | 75N93024C00008-0-9999-1 |
| Project ID | NIH-11178808 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals with infections caused by antibiotic-resistant bacteria or those at risk of emerging infectious diseases.
✕Less likely to help
Patients with infections that are not caused by antibiotic-resistant bacteria or those with non-infectious conditions may not receive any benefit from this research.
What this research studies
This research focuses on creating new therapeutic candidates to combat antibiotic-resistant infections and emerging infectious diseases. It involves a series of steps including optimizing drug leads, selecting the best candidates, and conducting preclinical studies to ensure safety and efficacy. Patients may benefit from innovative treatments that could be developed through this process, particularly for conditions that currently have limited options. The research aims to address critical health threats posed by resistant bacteria and emerging pathogens.
Why it matters
Potential benefit: If successful, this research could lead to new and effective treatments for patients suffering from antibiotic-resistant infections and emerging infectious diseases.
How similar studies have gone: Previous research has shown success in developing new therapies for antibiotic-resistant infections, indicating that this approach has potential for meaningful advancements.
Where this research is happening
-
Global Alliance for Tb Drug Development
New York, United States Active
Researchers
- Principal investigator: Fotouhi, Nader — Global Alliance for Tb Drug Development
- Study coordinator: Fotouhi, Nader
Related research
Other NIH-funded projects on the same topics.
-
Long-acting TB treatment option for people living with HIV
A new long-acting injectable TB regimen is being developed to shorten treatment and help people living with HIV who have TB.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.